证券代码：301060 证券简称：兰卫医学 公告编号：2025-044 上海兰卫医学检验所股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会不涉及变更前次股东会已通过的决议的情形。 上海兰卫医学检验所股份有限公司（以下简称"公司"）2025 年第二次临时股东会 于 2025 年 11 月 14 日在公司会议室召开，会议通知已于 2025 年 10 月 28 日以公告形式 发出，本次会议以现场投票与网络投票相结合的方式召开。会议由公司董事长曾伟雄先 生主持。 一、会议召开和出席情况 1、会议召开时间： 现场会议时间：2025 年 11 月 14 日 15:00。 出席会议的其他人员： （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 14 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系 统投票的具体时间为 2025 年 11 月 14 日 9:15 至 1 ...

Core Insights - The medical testing industry is facing significant challenges due to increased accounts receivable and declining profits, particularly following the COVID-19 pandemic [1][4][5] Group 1: Accounts Receivable and Financial Performance - Four companies have accounts receivable exceeding 2 billion yuan, with Capbio (凯普生物) involved in lawsuits to recover 357 million yuan in overdue payments [1] - In the first three quarters of this year, at least seven medical testing companies reported net losses attributable to shareholders, with six of them expected to continue this trend into 2024 [1] - Specific losses reported include: Puni Testing (谱尼测试) at 199 million yuan, RunDa Medical (润达医疗) at 163 million yuan, and Capbio at 128 million yuan [1] Group 2: Impact of Price Reductions and Impairment Provisions - Price reductions in the testing sector have led to widespread profit shrinkage among medical testing companies, with some firms making impairment provisions for accounts receivable [4] - Companies like KingMed Diagnostics (金域医学) have made significant impairment provisions, totaling 345 million yuan, primarily for accounts receivable, which reduced their consolidated profit by the same amount [4] - Lanwei Medical (兰卫医学) reported a total impairment provision of 16.73 million yuan, with 13.50 million yuan specifically for accounts receivable [5] Group 3: Recovery Trends and Future Outlook - The Ministry of Finance has indicated a commitment to debt reduction policies, which may accelerate the collection of accounts receivable from public hospitals [5] - Companies are implementing strategies to manage accounts receivable more effectively, with Puni Testing focusing on tailored collection strategies for major clients [6] - DiAn Diagnostics (迪安诊断) anticipates improved collection trends in the second half of the year, with expectations that all COVID-related accounts receivable will be fully provisioned by year-end [5][6]

Group 1 - The core viewpoint of the news is that Lanwei Medical has experienced a decrease in revenue and a significant increase in net profit, indicating a potential shift in financial performance despite lower sales [2] - As of November 12, Lanwei Medical's stock price increased by 0.79%, with a trading volume of 60.54 million yuan, and a net financing buy of -3.23 million yuan, suggesting a cautious investor sentiment [1] - The company's financing balance is at 86.68 million yuan, which is 2.12% of its market capitalization, indicating a low level of financing compared to the past year [1] Group 2 - For the period from January to September 2025, Lanwei Medical reported an operating income of 1.102 billion yuan, a year-on-year decrease of 16.51%, while the net profit attributable to the parent company was -667,700 yuan, reflecting a year-on-year increase of 98.35% [2] - The number of shareholders as of September 30 is 21,700, a decrease of 6.26% from the previous period, while the average circulating shares per person increased by 6.68% to 16,564 shares [2] - Since its A-share listing, Lanwei Medical has distributed a total of 320 million yuan in dividends, with 200 million yuan distributed over the past three years [3]

Core Viewpoint - The A-share market shows a slight decline with the Shanghai Composite Index closing at 3997.56 points, down 0.25%, while the total trading volume reached 20202.05 billion yuan, indicating a mixed performance among stocks breaking through the annual line [1] Group 1: Stock Performance - A total of 52 A-shares have surpassed the annual line today, with notable stocks including Luzhou Laojiao, Qiaoyuan Co., and Jiachuan Vision, which have deviation rates of 6.56%, 5.10%, and 4.86% respectively [1] - Stocks with smaller deviation rates that have just crossed the annual line include Lubnorth Chemical, Phoenix Optical, and Wuzhou Special Paper [1] Group 2: Individual Stock Data - Luzhou Laojiao (000912) saw a price increase of 9.93% with a turnover rate of 2.87%, closing at 4.87 yuan, resulting in a deviation rate of 6.56% [1] - Qiaoyuan Co. (301286) increased by 14.19% with a turnover rate of 9.67%, closing at 30.66 yuan, with a deviation rate of 5.10% [1] - Jiachuan Vision (300264) rose by 5.38% with a turnover rate of 10.65%, closing at 6.27 yuan, leading to a deviation rate of 4.86% [1]

Core Insights - Lanwei Medical (301060.SZ) released its Q3 2025 report, indicating that as of October 27, 2025, four institutional investors hold a total of 179 million shares, representing 44.67% of the company's total equity [1] - The institutional ownership decreased by 2.16 percentage points compared to the previous quarter [1] - A total of 50 public funds were disclosed this period, including notable funds such as GF Quantitative Multi-Factor Mixed A and E Fund CSI 2000 Index Enhanced A [1] - One new foreign institution, BARCLAYS BANK PLC, disclosed its holdings this quarter [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日召开 了第四届董事会第七次会议，审议了《关于公司拟购买董责险并授权公司管理层办理相 关事宜的议案》，为进一步完善公司风险管理体系，促进公司董事、高级管理人员充分 行使职权、履行职责，降低公司治理和运营风险，根据《上市公司治理准则》的有关规 定，公司拟为公司及全体董事、高级管理人员购买董监高责任保险（以下简称"董责险"）。 现将相关情况公告如下： 一、董责险方案 证券代码：301060 证券简称：兰卫医学 公告编号：2025-042 上海兰卫医学检验所股份有限公司 关于公司拟购买董责险的公告 1、第四届董事会第七次会议决议； 2、第四届董事会薪酬与考核委员会第三次会议决议。 1、投保人：上海兰卫医学检验所股份有限公司 2、被保险人：公司及公司全体董事、高级管理人员 3、赔偿限额：不超过人民币 5,000 万元（具体以与保险公司最终签订的保险合同 为准） 4、保险费用：不超过 20 万元（具体以与保险公司最终签订的保险合同为准） 5 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2025-041 （一）本次计提资产减值准备的原因 为真实地反映公司财务状况和经营成果，本着谨慎性原则，依据《企业会计准则》 及公司会计政策的相关规定，公司对 2025 年 9 月 30 日期末应收款项、存货、长期股权 投资、固定资产、无形资产等资产进行了全面清查，对各项资产减值的可能性、各类存 货的可变现净值等进行了充分的评估和分析。 （二）本次计提资产减值准备的资产范围及金额 公司对 2025 年 9 月 30 日存在可能发生减值迹象的资产进行全面清查和资产减值测 试后，计提 2025 年前三季度（1-9 月）各项资产减值准备共计 1,673.86 万元。具体如下 表： 单位：万元 | 项目 | 2025 年 1-9 月计提金额 | | --- | --- | | 应收票据坏账准备 | -52.11 | | 应收账款坏账准备 | 1,438.43 | | 其他应收款坏账准备 | -36.14 | | 合同资产减值 | 4.89 | 上海兰卫医学检验所股份有限公司 关于 2025 年前三季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的 ...

Core Insights - The company reported a third-quarter revenue of 343 million yuan, representing a year-on-year decline of 20.63% [1] - The net profit for the third quarter was 5.1154 million yuan, showing a significant year-on-year increase of 109.11% [1] - For the first three quarters, the total revenue was 1.102 billion yuan, down 16.51% compared to the previous year [1] - The net profit for the first three quarters showed a loss of 667,700 yuan, a decline of 98.35% year-on-year [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日召开 了第四届董事会第七次会议，审议通过了《关于提请召开公司 2025 年第二次临时股东 会的议案》，决定于 2025 年 11 月 14 日（星期五）召开公司 2025 年第二次临时股东会。 现将会议相关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：公司董事会 3、会议召开的合法、合规性：经公司第四届董事会第七次会议审议通过，决定召 开公司 2025 年第二次临时股东会。本次股东会的召集、召开符合有关法律、行政法规、 部门规章、规范性文件、深圳证券交易所业务规则和《上海兰卫医学检验所股份有限公 司章程》等规定。 证券代码：301060 证券简称：兰卫医学 公告编号：2025-043 上海兰卫医学检验所股份有限公司 关于召开 2025 年第二次临时股东会的通知公告 议。 网 络 投 票 ： 公 司 将 通 过 深 交 所 交 易 系 统 和 互 联 网 投 票 系 统 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 上海兰卫医学检验所股份有限公司（以下简称"公司"）第四届董事会第七次会议 于 2025 年 10 月 24 日在公司会议室以现场结合通讯会议方式召开。召开本次会议的通 知已于 2025 年 10 月 17 日以邮件形式通知全体董事。会议由公司董事长曾伟雄先生主 持，本次会议应出席董事 7 人，实际出席董事 7 人。本次会议的召集、召开和表决程序 符合《中华人民共和国公司法》《上海兰卫医学检验所股份有限公司章程》规定，会议 合法、有效。 二、董事会会议审议情况 经与会董事认真审议，充分讨论，审慎表决，本次会议审议通过了以下议案： 1、审议通过《关于公司 2025 年第三季度报告的议案》 证券代码：301060 证券简称：兰卫医学 公告编号：2025-040 上海兰卫医学检验所股份有限公司 第四届董事会第七次会议决议公告 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的《2025 年第 三季度报告》（公告编号：2025-039）。 表决结果：同意 7 票，反对 0 ...